作者：
Yiqing,Yang [1]
;
Albert,Dashi [2]
;
Poh Loong,Soong [3]
;
Kun Han,Lin [4]
;
Wilson L W,Tan [2]
;
Bangfen,Pan [2]
;
Matias I,Autio [5]
;
Zenia,Tiang [2]
;
Robin J G,Hartman [6]
;
Heming,Wei [7]
;
Matthew Andrew,Ackers-Johnson [2]
;
Bing,Lim [8]
;
Anna,Walentinsson [9]
;
Vidhya Vardharajan,Iyer [10]
;
Malin K B,Jonsson [11]
;
Roger S,Foo [12]
作者单位：
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cardiovascular Research Institute, National University Healthcare Systems, Singapore; NUS Graduate School, National University of Singapore, Singapore.
[1]
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cardiovascular Research Institute, National University Healthcare Systems, Singapore.
[2]
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cardiovascular Research Institute, National University Healthcare Systems, Singapore; Ternion Biosciences, Singapore.
[3]
Ternion Biosciences, Singapore.
[4]
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cardiovascular Research Institute, National University Healthcare Systems, Singapore; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore.
[5]
University of Utrecht, Heidelberglaan 8, 3584 CS Utrecht, the Netherlands; Translational Science & Experimental Medicine, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
[6]
National Heart Research Institute Singapore (NHRIS), National Heart Centre, Singapore.
[7]
Sana Biotechnology, 300 Technology Square, Cambridge, MA 02139, United States of America.
[8]
Translational Science & Experimental Medicine, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
[9]
Bioscience Cardiovascular, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Uppsala University, Uppsala, Sweden.
[10]
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Bioscience Cardiovascular, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
[11]
Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cardiovascular Research Institute, National University Healthcare Systems, Singapore; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore. Electronic address: roger.foo@nus.edu.sg.
[12]
DOI
10.1016/j.yjmcc.2024.10.009
PMID
39490643
发布时间
2024-11-25
换一批
换一批
